Decrease of voriconazole trough levels during therapy with enteral nutrition: a case report

Hiromi Kaneko, Shingo Yamazaki, Masashi Uchida, Takaaki Suzuki, Kentaro Murakami, Hisahiro Matsubara, Katsuhiro Kamei and Itsuko Ishii

Abstract
Background: Voriconazole (VRCZ) is the first-line therapy for chronic pulmonary aspergillosis and is available in both intravenous and oral formulations. The bioavailability of the oral form is estimated to be over 90% in healthy volunteers. Some drugs are reported to interact with enteral nutrition (EN), but there are few reports about the trough levels of VRCZ during EN therapy. Here, we describe changes in the VRCZ trough levels in a patient receiving continuous EN therapy.

Case presentation: The patient was a 58-year-old man with esophageal cancer and a history of partial pulmonary resection due to aspergilloma. He was taking oral VRCZ tablets and his VRCZ trough level was about 2 μg/mL before esophageal cancer surgery. Following esophagectomy, VRCZ was restarted on postoperative day 16. Crushed VRCZ tablets were administered via a jejunostomy tube because of swallowing difficulty. He was also receiving EN, which was interrupted only during the administration of VRCZ. When we checked his VRCZ level 5 days after restarting VRCZ, the trough level was 0.80 μg/mL. After increasing the VRCZ dose, reducing EN, and changing the administration route from jejunostomy tube to oral, his trough level increased to 1.87 μg/mL.

Conclusions: A decrease in the VRCZ trough level was observed when VRCZ was administered via a jejunostomy tube while the patient was receiving continuous EN. Careful monitoring of VRCZ levels is needed in such cases.

Keywords: Voriconazole, Enteral nutrition, Jejunostomy tube feeding, Therapeutic drug monitoring, Drug interaction

Introduction
Voriconazole (VRCZ), an antifungal triazole, is the first-line therapy for chronic pulmonary aspergillosis [1]. It is available in both intravenous and oral formulations, and oral therapy is a useful option for outpatients.

VRCZ is metabolized mainly by cytochrome P450 (CYP) 2C19 and to a lesser extent by CYP3A4 and CYP2C9 [2]. Poor metabolizers achieve 4-fold higher VRCZ levels than extensive metabolizers [3]. VRCZ trough levels below 1.0 μg/mL are associated with lack of response to therapy [4]. On the other hand, high trough levels are associated with serious toxicity such as neurotoxicity and hepatotoxicity [5]. Hamada et al. reported that an appropriate trough level for increasing clinical success while minimizing toxicity is 1.0–4.0 μg/mL [6], and therefore therapeutic drug monitoring is needed.

The absorption of VRCZ tablets is a first-order process, and the bioavailability exceeds 90% according to data from healthy volunteers [7]. VRCZ bioavailability is
reduced by approximately 20% when administered with high-fat meals [8]. Although administration between meals is indicated in the package insert [3], it is difficult to administer VRCZ between meals in patients who are receiving continuous enteral nutrition (EN). Early EN reduces the incidence of life-threatening surgical complications [9], and an EN strategy is obviously important for those who cannot take food orally. However, some drug interactions with continuous EN have been reported [10].

Williams reported that continuous EN via a nasojejunal catheter for 24 h caused a decrease in the trough level of orally administered VRCZ from therapeutic levels to undetectable levels [11]. Although VRCZ levels when administered via a tube have been reported [12, 13], the backgrounds of the patients differed and detailed information on EN was not described.

Here, we describe the temporal changes in VRCZ trough levels in a patient with esophageal cancer before and after starting continuous EN therapy over the entire clinical course.

**Case**

The patient was a 58-year-old Japanese man with stage III (T3N3M0) esophageal cancer who was scheduled for neoadjuvant chemotherapy and surgery. He had a history of partial pneumonectomy for chronic pulmonary aspergillosis and required antifungal agent therapy to avoid relapse of the pulmonary aspergillosis.

VRCZ tablets were initiated at a dose of 200 mg (3.8 mg/kg) twice daily at 06:00 and 18:00. At days 27 and 41 after starting VRCZ, trough levels were 1.93 μg/mL and 2.46 μg/mL, respectively. The only other concomitant drug in the preoperative period was magnesium oxide (Table 1). The patient received five courses of chemotherapy before surgery. During chemotherapy, the VRCZ tablets were changed to micafungin (MCFG) injections because he could not tolerate oral drugs due to nausea.

After the end of chemotherapy, the VRCZ tablets were re-introduced. Sixteen days later, on the day before surgery, the VRCZ trough level was 2.12 μg/mL and the C-reactive protein (CRP) value was 1.39 mg/dL (Fig. 1). The patient underwent right thoracic esophagectomy and jejunostomy. There was an increase in CRP to 13.38 mg/dL on postoperative day (POD) 9, due to aspiration pneumonia, which decreased over time. The CRP value was 2.57 mg/dL on POD 16. EN with Hine E-Gel® was started the same day. The administration method was 15 h continuous during the daytime, from 07:00 to 22:00. Hine E-Gel® contains low-molecular peptides and amino acids and the proportion of fat is 20.3% (Table 2). From the day of the operation to POD 15, oral VRCZ administration was changed to MCFG injections. On POD 16, VRCZ was restarted via a jejunostomy tube. VRCZ tablets were crushed and suspended in water. The VRCZ dosing regimen was the same as before the esophagectomy: 200 mg twice daily at 06:00 and 18:00. On PODs 16–23, at 18:00, the administration of EN was stopped just before the administration of VRCZ. The line was flushed with water, VRCZ was administered immediately, and the line was again flushed with water. EN was restarted soon after. All concomitant drugs in the postoperative period are listed in Table 1. On POD 21, the VRCZ trough level was 0.80 μg/mL and the CRP value was 1.44 mg/dL (Fig. 1). There were no episodes of severe diarrhea, which could have caused malabsorption and changes in body weight. The jejunostomy tube was inserted 25 cm from ligament of Treitz and a check of the positioning revealed no apparent problems.

We considered the possibility of an interaction between VRCZ and EN and temporarily stopped EN 1 h before and 1 h after VRCZ administration from POD 24. On PODs 24–66, EN was clamped at 17:00, 1 h before VRCZ administration at 18:00. After flushing the line with water, VRCZ was administered immediately, and the line was again flushed with water. EN was started at 19:00, 1 h after the administration of VRCZ. However, the trough level was 0.50 μg/mL on POD 34 (Fig. 1). When examined again on POD 48 and POD 56, the levels were still under the therapeutic range at 0.43 μg/mL and 0.90 μg/mL, respectively (Fig. 1). We confirmed that his adherence was good and there were no episodes of tube obstruction. The patient's general status was relatively good, and the CRP value was 0.21 mg/dL on POD 48. On POD 56, CRP had increased to 0.51 mg/dL, which might be explained by an aspiration episode. However, this was not too severe and the patient soon recovered. The duration of interruption to EN could not be extended further because faster administration caused diarrhea.

On POD 61, VRCZ was increased to 250 mg (4.9 mg/kg) twice daily, administered at 06:00 and 18:00. On

### Table 1 List of drugs administered concomitant with VRCZ oral tablets in this case

| Drug administered                        | Dose   | Frequency |
|-----------------------------------------|--------|-----------|
| Preoperative period                     |        |           |
| Magnesium oxide                         | 500 mg | TID       |
| Postoperative period                    |        |           |
| Lansoprazole                            | 15 mg  | SID       |
| Sodium chloride                         | 2.5 g  | TID       |
| Mosapride citrate hydrate               | 5 mg   | TID       |
| Rikkunshito extract                     | 2.5 g  | TID       |
| Bromhexine hydrochloride                | 4 mg   | TID       |
| Acotiamide hydrochloride hydrate        | 100 mg | TID       |

TID three times a day, SID once a day
POD 67, the administration route was switched from jejunostomy tube to oral after stable swallowing function was confirmed. At the same time, the patient resumed oral feeding and EN was reduced from 15 h continuous infusion to 8 h continuous infusion, from 08:00 to 16:00. This allowed a 2-h interval between EN and VRCZ administration. On POD 69, 2 days after EN was reduced, the trough level was 1.87 μg/mL (Fig. 1). The CRP value on POD 69 was 0.37 mg/dL. At the same time, an increase in the γ-glutamyl transpeptidase (γ-GTP) level was observed. On POD 73, the γ-GTP increase reached grade 3 according to the Common Terminology Criteria for Adverse Events version 5.0 [14] and VRCZ administration was discontinued. The VRCZ trough level 3 days after stopping VRCZ was 0.45 μg/mL. The γ-GTP level decreased at the same time. We decided against VRCZ rechallenge and were continuing to monitor the patient for signs of a recurrence of fungal infection.

Discussion and conclusion

After esophagectomy, we observed that the VRCZ trough level was decreased to below the therapeutic level on POD 21, 5 days after VRCZ was restarted. Among the concomitant drugs administered in the postoperative period (Table 1), lansoprazole is metabolized by the same enzymes as VRCZ. Fang reported that VRCZ levels increased when combined with lansoprazole [16]. However, there are no reports on the concomitant drugs used in our case that could affect VRCZ metabolism and cause a decrease in serum levels.

VRCZ levels were measured by high-performance liquid chromatography with minor modifications of the method of Pennick et al. [15] All blood samples for the measurement of VRCZ trough levels were collected before 06:00. Plasma VRCZ was extracted using a solid extraction column (ISOLUTE® SLE+, Biotage, Japan). The analytical column was a CAPCELL PAK C18 MG (5 mm, 250 × 4.6 mm, Osaka Soda, Japan), and the ultraviolet wavelength for VRCZ was 257 nm. The minimum limit of quantitation was 0.25 μg/mL.

Table 2 Nutritional content of Hine E-Gel® started for enteral nutrition in this case

| Composition | Content (g/100 mL) | Energy to total calories (%) |
|-------------|--------------------|-----------------------------|
| Calorie     | 80 kcal            | 16.4                        |
| Protein     | 3.2 g              | 16.4                        |
| Fat         | 1.8 g              | 20.3                        |
| Carbohydrate| 12.3 g             | 63.2                        |
| Dietary fiber| 1.1 g             |                              |
| Sodium      | 133 mg             |                              |
two similarities between our case and Williams’ case: the EN used contained a relatively high proportion of fat (20.3% in our case) and it was administered continuously. On the other hand, crushed VRCZ tablets were administered via a jejunostomy tube in our case, whereas VRCZ suspension was orally administered in Williams’ case. Two other studies on VRCZ levels after administration via a tube have reported that the levels were in the therapeutic range [12, 13]. However, no detailed information was given on EN status, such as composition, calories, and duration. Taken together, we consider that tube administration itself is a useful route and that continuous EN with a relatively high fat content seems to have played an important role in the decrease in VRCZ trough levels in our case.

On days 24–66, we tried stopping the EN between 17:00 and 19:00 for VRCZ administration at 18:00, but its trough levels remained below the therapeutic range. The time to peak concentration of VRCZ varies by 1.7–3.0 h in patients at high risk of developing fungal infections [17]. Hence, a 1-h interval might not have been sufficient for our patient to avoid an interaction with EN.

On PODs 16–60, the VRCZ trough levels varied from 0.43 μg/mL to 0.90 μg/mL. There was no change in the concomitant drugs administered or in liver function. Although inflammation, reflected by CRP levels, has been reported to be associated with VRCZ trough levels [18], there was no apparent increase in CRP during this period. Therefore, we consider the changes in VRCZ trough levels on PODs 21, 34, 48, and 56 might have been caused by intra-individual variability.

On POD 67, the route of VRCZ administration was changed from tube to oral. Given that the jejunostomy tube was 25 cm from the ligament of Treitz, we consider that there was enough length for the absorption of

| Study type       | Williams11 | Martinez et al12 | Mohammedi et al13 |
|------------------|------------|------------------|-------------------|
| VRCZ dose        | 11.6 mg/kg/day | 8 mg/kg/day     | 6.2 ± 1.1 mg/kg/day |
| VRCZ formulation, Administration route | Suspension, Per oral | Crushed VRCZ tablets, Jejunostomy tube | Crushed VRCZ tablets, Nasogastric tube |
| Nutritional route | Nasojejunal tube | NR | Nasogastric tube |
| Type of EN (composition) | ISOSOURCE® HN (29% caloric content of fat) | NR | NR |
| EN method        | Continuous | NR | Interrupted only for the duration of VRCZ administration |
| Patients, Age    | 1 post-transplantion, age 13 years | 1 with esophageal cancer, age 66 years | 6 with hematological malignancies (4 acute leukemia, 2 myeloma), 1 with solid tumor, and 1 with invasive pulmonary aspergillosis, age 63 ± 12 years |
| Patients, Race   | Hispanic | NR | NR |
| The purpose of VRCZ therapy | Prophylactic therapy | Candida glabrata infection | 4 patients, voriconazole therapy was given for a microbiologically documented fungal infection. In total, five fungal pathogens were isolated (4 Aspergillus fumigatus and 1 Candida kefyr). |
| Serum VRCZ levels (days after starting tube administration) | 1.07 mg/dL decreased to undetectable (On day8, 15) it was not mentioned that whether these were trough levels or not. | Ctrough: 1.7, 1.75, 1.4 mg/L Cpeak: 2.5, 2.55, 2.6 mg/L (On days 2, 8, 28) | Ctrough: 4.6 ± 2.8 mg/L Cpeak: 6.4 ± 4.3 mg/L (On days 3–44, mean 16 days) |
| Assay method     | NR | Solid-phase extraction followed by reversed liquid phase chromatography with UV detection. | Solid-phase extraction followed by reversed liquid phase chromatography with UV detection |

NR, data not reported
drugs. In an in vitro study, it has been reported that the recovery rate after infusion with VRCZ suspension through an enteral feeding tube is 99.3 ± 10.3% after the tube is flushed twice with 20 mL of distilled water [19]. This indicates that the change in the route of administration of VRCZ had little effect on the increased VRCZ level on POD 69. On POD 67, EN was also reduced from 2000 kcal to 800 kcal and a 2-h interval was instituted between VRCZ and EN administration. We believe that this reduction in EN caused recovery of VRCZ absorption and the increase in VRCZ trough level.

The duration of VRCZ trough levels below 1.0 μg/mL on PODs 21–56 corresponded to when the patient received continuous EN therapy with Hine E-Gel®. Therapeutic drug monitoring is therefore essential to maintain the appropriate VRCZ trough levels. In the case of severe infection, it might be advisable to switch from oral VRCZ tablets to injections in patients receiving continuous EN therapy.

In conclusion, even though the oral formulation of VRCZ has high bioavailability, VRCZ levels should be monitored carefully when the patient’s EN status changes.

Abbreviations

VRCZ: Voriconazole; EN: Enteral nutrition; CYP: Cytochrome P450; MCFG: Micafungin; POD: Postoperative day; CRP: C-reactive protein; γ-GTP: γ-glutamyl transpeptidase; i.v.: Intravenous injection; TPN: Total parenteral nutrition; AST: Aspartate transaminase; ALT: Alanine aminotransferase

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s40780-021-00237-4.

Additional file 1. Bayesian-predicted concentration curve of VRCZ. The mean values of the default population pharmacokinetic parameters for VRCZ in VFEND® TDM tool version 1.2 (Pfizer, Japan) were as follows: Ka, 0.654 /h; Km, 3.850 mg/L; Distribution Volume of central compartment, 97.9 L; Vmax, 29.631 mg/h; F, 1.000; lag-time, 0.190 h. The individual VRCZ level of days after dose escalation was predicted by the Bayesian method. The observed VRCZ trough levels during enteral nutrition were used for the analysis. The VRCZ dose was increased from 200 mg every 12 h to 250 mg every 12 h on POD 61, and the predicted VRCZ trough level 9 days after the dose increased (POD 69) was 1.00 μg/mL.

Acknowledgements

We thank both the pharmacy and gastrointestinal unit staff of Chiba University Hospital.

Authors’ contributions

HK wrote a first draft of this manuscript. SY, MU, and TS advised on the interpretation of pharmacokinetics in this case and revised the manuscript. KM advised on the interpretation of the therapeutic course in this case and revised the manuscript. HM, KK and II supervised the writing of the manuscript. All authors read and approved the final manuscript.

Funding

No funding was received for this report.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Informed consent for publication of this case report was obtained from the patient.

Competing interests

The authors declare that they have no competing interests.

Author details

1Division of Pharmacy, University Hospital, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba City, Chiba 260-8677, Japan. 2Department of Frontier Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba City, Chiba 260-8670, Japan. 3Medical Mycology Research Center, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba City, Chiba 260-8673, Japan.

Received: 15 September 2021 Accepted: 16 December 2021

Published online: 03 February 2022

References

1. Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and Management of Aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1–e60. https://doi.org/10.1093/cid/ciw326.
2. Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos. 2003;31(5):540–7. https://doi.org/10.1121/dmd.31.5.540.
3. VFEND® Tablets [package insert]. Tokyo: Pfizer Inc; 2018.
4. Piscual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46(2):201–11. https://doi.org/10.1086/524669.
5. Jin H, Wang T, Falcione BA, Olsen KM, Chen K, Tang H, et al. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis. J Antimicrob Chemother. 2016;71(7):1772–85. https://doi.org/10.1093/jac/dkw045.
6. Hamada Y, Tokimatsu I, Mikamo H, Kimura M, Seki M, Takakura S, et al. Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother. 2013; 19(3):381–92. https://doi.org/10.1007/s10156-013-0607-8.
7. Urusa T, Franziska I, Hartmut D. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 2006;45(7):649–63. https://doi.org/10.21
65/00003088-200645070-00002.
8. Perkins L, Wood N, Kleinemann D, Greenhalgh K, Nichols D. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol. 2003;56(Suppl 1):17–23. https://doi.org/10.1046/j.1365-2125.2003.01994.x.
9. Fujita T, Daiko H, Nishimura M. Early enteral nutrition reduces the rate of life-threatening complications after thoracic esophagectomy in patients with esophageal cancer. Eur Surg Res. 2012;48(2):79–84. https://doi.org/10.1159/000336574.
10. Paul DW, Lan Z, Shelly G, et al. Recommendations for the use of medications with continuous enteral nutrition. Am J Health Syst Pharm. 2009;66(16):1458–67. https://doi.org/10.2146/japh.080632.
11. Williams D. The effect of enteral nutrition supplements on serum voriconazole levels. J Oncol Pharm Pract. 2012;18(1):128–31. https://doi.org/10.1177/1078155210396576.
12. Martinez V, Le Guillou JL, Lamer C, Le Jouan M, Tod M, Dromer F. Serum voriconazole levels following administration via percutaneous jejunostomy tube. Antimicrob Agents Chemother. 2003;47(10):3375. https://doi.org/10.1128/AAC.47.10.3375-01994.x.
13. Mohammadi I, Pio MA, Padoin C, Robert D. Plasma levels of voriconazole administered via a nasogastric tube to critically ill patients. Eur J Clin Microbiol Infect Dis. 2005;24(5):358–60. https://doi.org/10.1007/s10096-005-1325-7.
14. Cancer Therapy Evaluation Program in National cancer institute: Common Terminology Criteria for Adverse Events version 5.0. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50. Accessed 11 Oct 2021.

15. Pennick GJ, Clark M, Sutton DA, Rinaldi MG. Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob Agents Chemother. 2003;47(7):2348–50. https://doi.org/10.1128/AAC.47.7.2348-2350.2003.

16. Qi F, Zhu L, Li N, Ge T, Xu G, Liao S. Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole. Int J Antimicrob Agents. 2017;49(4):493–9. https://doi.org/10.1016/j.ijantimicag.2016.11.025.

17. Lazarus HM, Blumer JL, Yanovich S, Schlamm H, Romero A. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol. 2002;42(4):395–402. https://doi.org/10.1177/00912700222011445.

18. Van Wanrooy MJ, Span LF, Rodgers MG, et al. Inflammation is associated with voriconazole trough concentrations. Antimicrob Agents Chemother. 2014;58(12):7098–101. https://doi.org/10.1128/AAC.03020-14.

19. Tanaka R, Eto D, Goto K, Ohchi Y, Yasuda N, Suzuki Y, et al. Pharmacokinetic and adsorptive analyses of administration of oral voriconazole suspension via enteral feeding tube in intensive care unit patients. Biol Pharm Bull. 2021;44(5):737–41. https://doi.org/10.1248/bpb.b20-00796.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions